ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

BARDA awards Sanofi $226 million for egg-free flu vaccine

by Ryan Cross
December 12, 2019 | APPEARED IN VOLUME 97, ISSUE 48

The Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services, has awarded Sanofi Pasteur $226 million to develop egg-free influenza vaccines at its vaccine plant in Swiftwater, Pennsylvania. BARDA says the deal is part of its effort to prepare for the next influenza pandemic. Most flu vaccines are grown in eggs, but Sanofi already sells one biologic flu vaccine, Flublok Quadrivalent, made from recombinant DNA grown in cells.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment